In the News

Organoids Touted as Future of Brain Disorder R&D as AxoSim Scoops Up Tech from Vyant Subsidiary

October 24, 2023
Loading the Elevenlabs Text to Speech AudioNative Player...
As Vyant Bio continues its wind-down, the neuroscience research assets of its subsidiary StemoniX have officially been picked up by AxoSim, a New Orleans-based drug discovery biotech.

Related Stories

Spotlight
2/5/2026
Organoid Neurotoxicity Testing Embraced by FDA and NIH
Scientists and regulators have long acknowledged the weaknesses in traditional methods used to identify drugs that may harm the central nervous system.
Spotlight
2/5/2026
Modeling Myelination and Therapeutic Response in Demyelinating Disorders
CNS-3D and PNS-3D organoids support authentic myelin formation and enable high-throughput measurement of myelination for therapeutic screening.
Case Study
2/5/2026
Takeda Implements CNS-3D Organoids for Preclinical Neurotoxicity Assessment
CNS-3D organoids provide a human-relevant context for the detection of compound-induced neurotoxicity, supports multiplexed endpoint analysis, and reduces reliance on animal testing.
Join our mailing list.
Thank you! Your submission has been received.
Something went wrong while submitting the form.
© 2025 28bio. All rights reserved.
Privacy Policy
Terms of Use
FCOI Polcy